S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.60 (-0.87%)
AAPL   127.11 (-1.40%)
MSFT   212.60 (-0.20%)
FB   251.48 (+2.38%)
GOOGL   1,727.31 (-0.21%)
AMZN   3,103.49 (-0.77%)
TSLA   825.24 (-2.34%)
NVDA   515.00 (-2.46%)
BABA   243.27 (+0.12%)
CGC   33.40 (-3.52%)
GE   11.32 (-2.92%)
MU   80.73 (-0.70%)
AMD   88.13 (-2.93%)
T   29.19 (-0.34%)
NIO   56.27 (-7.56%)
F   9.82 (-3.44%)
ACB   12.02 (+0.50%)
BA   204.40 (-2.62%)
DIS   171.38 (-1.18%)
NFLX   498.02 (-0.57%)
GILD   63.34 (+1.51%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.60 (-0.87%)
AAPL   127.11 (-1.40%)
MSFT   212.60 (-0.20%)
FB   251.48 (+2.38%)
GOOGL   1,727.31 (-0.21%)
AMZN   3,103.49 (-0.77%)
TSLA   825.24 (-2.34%)
NVDA   515.00 (-2.46%)
BABA   243.27 (+0.12%)
CGC   33.40 (-3.52%)
GE   11.32 (-2.92%)
MU   80.73 (-0.70%)
AMD   88.13 (-2.93%)
T   29.19 (-0.34%)
NIO   56.27 (-7.56%)
F   9.82 (-3.44%)
ACB   12.02 (+0.50%)
BA   204.40 (-2.62%)
DIS   171.38 (-1.18%)
NFLX   498.02 (-0.57%)
GILD   63.34 (+1.51%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.60 (-0.87%)
AAPL   127.11 (-1.40%)
MSFT   212.60 (-0.20%)
FB   251.48 (+2.38%)
GOOGL   1,727.31 (-0.21%)
AMZN   3,103.49 (-0.77%)
TSLA   825.24 (-2.34%)
NVDA   515.00 (-2.46%)
BABA   243.27 (+0.12%)
CGC   33.40 (-3.52%)
GE   11.32 (-2.92%)
MU   80.73 (-0.70%)
AMD   88.13 (-2.93%)
T   29.19 (-0.34%)
NIO   56.27 (-7.56%)
F   9.82 (-3.44%)
ACB   12.02 (+0.50%)
BA   204.40 (-2.62%)
DIS   171.38 (-1.18%)
NFLX   498.02 (-0.57%)
GILD   63.34 (+1.51%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.60 (-0.87%)
AAPL   127.11 (-1.40%)
MSFT   212.60 (-0.20%)
FB   251.48 (+2.38%)
GOOGL   1,727.31 (-0.21%)
AMZN   3,103.49 (-0.77%)
TSLA   825.24 (-2.34%)
NVDA   515.00 (-2.46%)
BABA   243.27 (+0.12%)
CGC   33.40 (-3.52%)
GE   11.32 (-2.92%)
MU   80.73 (-0.70%)
AMD   88.13 (-2.93%)
T   29.19 (-0.34%)
NIO   56.27 (-7.56%)
F   9.82 (-3.44%)
ACB   12.02 (+0.50%)
BA   204.40 (-2.62%)
DIS   171.38 (-1.18%)
NFLX   498.02 (-0.57%)
GILD   63.34 (+1.51%)
Log in
NASDAQ:MRSN

Mersana Therapeutics Stock Forecast, Price & News

$21.06
+0.30 (+1.45 %)
(As of 01/15/2021 03:59 PM ET)
Add
Compare
Today's Range
$20.11
Now: $21.06▼
$21.26
50-Day Range
$18.12
MA: $24.02▼
$27.59
52-Week Range
$4.12
Now: $21.06▼
$29.09
Volume42,685 shs
Average Volume2.54 million shs
Market Capitalization$1.44 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.54
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Mersana Therapeutics logo

MarketRank™

Overall MarketRank™

1.56 out of 5 stars

Medical Sector

274th out of 1,480 stocks

Pharmaceutical Preparations Industry

148th out of 612 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRSN
Previous Symbol
CUSIPN/A
CIK1442836
Webwww.mersana.com
Phone617-498-0020
Employees83

Debt

Debt-to-Equity Ratio0.02
Current Ratio13.05
Quick Ratio13.05

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$42.12 million
Price / Sales34.25
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.64 per share
Price / Book12.84

Profitability

EPS (Most Recent Fiscal Year)($0.65)
Net Income$-28,210,000.00
Net Margins-8,772.91%
Return on Equity-45.16%
Return on Assets-37.53%

Miscellaneous

Outstanding Shares68,497,000
Market Cap$1.44 billion
Next Earnings Date2/26/2021 (Estimated)
OptionableNot Optionable
$21.06
+0.30 (+1.45 %)
(As of 01/15/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

How has Mersana Therapeutics' stock price been impacted by COVID-19?

Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRSN shares have increased by 226.5% and is now trading at $21.09.
View which stocks have been most impacted by COVID-19.

Is Mersana Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Mersana Therapeutics stock.
View analyst ratings for Mersana Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Mersana Therapeutics?

Wall Street analysts have given Mersana Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mersana Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, February 26th 2021.
View our earnings forecast for Mersana Therapeutics.

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced its quarterly earnings results on Monday, November, 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.31) by $0.02. The business earned $0.01 million during the quarter, compared to analysts' expectations of $0.43 million. Mersana Therapeutics had a negative return on equity of 45.16% and a negative net margin of 8,772.91%.
View Mersana Therapeutics' earnings history.

What price target have analysts set for MRSN?

6 analysts have issued 1-year price targets for Mersana Therapeutics' stock. Their forecasts range from $20.00 to $33.00. On average, they expect Mersana Therapeutics' share price to reach $27.80 in the next twelve months. This suggests a possible upside of 31.8% from the stock's current price.
View analysts' price targets for Mersana Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Mersana Therapeutics' key competitors?

Some companies that are related to Mersana Therapeutics include Emergent BioSolutions (EBS), Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Eidos Therapeutics (EIDX), Maravai LifeSciences (MRVI), PTC Therapeutics (PTCT), Arena Pharmaceuticals (ARNA), Hutchison China MediTech (HCM), ChemoCentryx (CCXI), Hypera (HYPMY), Atea Pharmaceuticals (AVIR), GW Pharmaceuticals (GWPH), Arvinas (ARVN), Reata Pharmaceuticals (RETA) and Apellis Pharmaceuticals (APLS).
View all of MRSN's competitors.

What other stocks do shareholders of Mersana Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology Group (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS).

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the following people:
  • Ms. Anna Protopapas, Pres, CEO & Director (Age 57, Pay $833.15k)
  • Mr. Brian C. DeSchuytner, Sr. VP of Fin. & Product Strategy (Age 43, Pay $456.82k)
  • Mr. Mikhail Papisov Ph.D., Co-Founder
  • Mr. Ashish Mandelia, VP, Controller & Principal Accounting Officer (Age 47)
  • Dr. Timothy B. Lowinger, Chief Science & Technology Officer (Age 57)
  • Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications
  • Ms. Radha Iyengar, VP of Legal Operations
  • Dr. Michael Kaufman, Chief Manufacturing Officer (Age 63)
  • Mr. Chuck Miller, Sr. VP of Regulatory Affairs
  • Mr. Marc Damelin, Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $21.09.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $1.44 billion and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Mersana Therapeutics employs 83 workers across the globe.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is www.mersana.com.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.